MX342641B - Metodos para uso de un agente adenoviral anti-angiogenico especifico. - Google Patents
Metodos para uso de un agente adenoviral anti-angiogenico especifico.Info
- Publication number
- MX342641B MX342641B MX2012007849A MX2012007849A MX342641B MX 342641 B MX342641 B MX 342641B MX 2012007849 A MX2012007849 A MX 2012007849A MX 2012007849 A MX2012007849 A MX 2012007849A MX 342641 B MX342641 B MX 342641B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- specific anti
- angiogenic
- adenoviral agent
- agent
- Prior art date
Links
- 230000001772 anti-angiogenic effect Effects 0.000 title abstract 2
- 241000701161 unidentified adenovirus Species 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28222810P | 2010-01-05 | 2010-01-05 | |
| US28224710P | 2010-01-07 | 2010-01-07 | |
| PCT/IL2011/000007 WO2011083464A2 (en) | 2010-01-05 | 2011-01-05 | Methods for use of a specific anti-angiogenic adenoviral agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012007849A MX2012007849A (es) | 2012-10-09 |
| MX342641B true MX342641B (es) | 2016-10-07 |
Family
ID=44305892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007849A MX342641B (es) | 2010-01-05 | 2011-01-05 | Metodos para uso de un agente adenoviral anti-angiogenico especifico. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9567605B2 (enExample) |
| EP (2) | EP3159405B8 (enExample) |
| JP (2) | JP6196040B2 (enExample) |
| KR (1) | KR101754437B1 (enExample) |
| AU (1) | AU2011204405B2 (enExample) |
| CA (1) | CA2786374C (enExample) |
| DK (2) | DK2521776T3 (enExample) |
| MX (1) | MX342641B (enExample) |
| NZ (1) | NZ601324A (enExample) |
| SG (2) | SG10201500013SA (enExample) |
| WO (1) | WO2011083464A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| NZ532348A (en) | 2001-10-19 | 2006-06-30 | Vascular Biogenics Ltd | Polynucleotide constructs comprising ligand binding domains, effector domains of apoptosis signaling molecules and a promoter or enhancer and their use in gene therapy |
| JP5513885B2 (ja) | 2006-07-31 | 2014-06-04 | ヴァスキュラー バイオジェニックス リミテッド | ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用 |
| JP6151515B2 (ja) | 2010-01-05 | 2017-06-21 | バスキュラー バイオジェニックス リミテッド | 神経膠芽腫ｇｂｍを治療するための組成物および方法 |
| US9567605B2 (en) | 2010-01-05 | 2017-02-14 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
| SI2908865T1 (sl) * | 2012-10-17 | 2019-02-28 | Vascular Biogenics Ltd. | Adenovirus, ki izraža Fas himero in uporaba le-tega v postopkih zdravljenja raka |
| US9511046B2 (en) * | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| WO2014118643A2 (en) | 2013-02-04 | 2014-08-07 | Vascular Biogenics Ltd. | Methods of inducing responsiveness to anti-angiogenic agent |
| EP3223824B1 (en) | 2014-11-26 | 2021-01-06 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
| US20210322574A1 (en) | 2017-10-20 | 2021-10-21 | Vascular Biogenics Ltd. | Diagnostic methods for anti-angiogenic agent therapy |
| US10525127B2 (en) * | 2018-03-31 | 2020-01-07 | Femtomab | P14.7 protein and uses thereof as vaccine adjuvant |
| AU2019286345A1 (en) * | 2018-06-13 | 2021-01-07 | The Council Of The Queensland Institute Of Medical Research | Viral detection assay |
| BR112021017780A2 (pt) * | 2019-03-13 | 2022-02-01 | Vascular Biogenics Ltd | Métodos de terapia anti-tumor |
| SG11202109441UA (en) | 2019-04-12 | 2021-09-29 | Vascular Biogenics Ltd | Methods of anti-tumor therapy |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5747340A (en) | 1994-06-03 | 1998-05-05 | Syntex (U.S.A.) Inc. | Targeted gene expression using preproendothelin-1 promoters |
| EP1707631A3 (en) | 1996-11-20 | 2006-12-27 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US6204055B1 (en) | 1999-04-12 | 2001-03-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of Fas mediated signaling |
| US7691370B2 (en) | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
| US6649158B1 (en) | 1998-10-15 | 2003-11-18 | Canji, Inc. | Methods and compositions to induce antitumor response |
| EP1185627A2 (en) | 1999-06-01 | 2002-03-13 | Cornell Research Foundation, Inc. | Activation of dendritic cells to enhance immunity |
| IL130608A0 (en) | 1999-06-23 | 2000-06-01 | Compugen Ltd | Novel nucleic and amino acid sequence |
| US6867022B1 (en) * | 2000-01-21 | 2005-03-15 | Regents Of The University Of Michigan | Replication deficient adenovirus vectors and methods of making and using them |
| AU2003222427B8 (en) | 2000-11-17 | 2010-04-29 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US7067649B2 (en) * | 2000-11-17 | 2006-06-27 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same |
| US20100282634A1 (en) | 2000-11-17 | 2010-11-11 | Dror Harats | Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis |
| US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| US20070286845A1 (en) | 2000-11-17 | 2007-12-13 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| DK2186530T3 (da) | 2000-11-17 | 2013-07-29 | Vascular Biogenics Ltd | Promotere, der udviser endothelcellespecificitet og fremgangsmåder til anvendelse heraf |
| US8039261B2 (en) | 2000-11-17 | 2011-10-18 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| NZ532348A (en) * | 2001-10-19 | 2006-06-30 | Vascular Biogenics Ltd | Polynucleotide constructs comprising ligand binding domains, effector domains of apoptosis signaling molecules and a promoter or enhancer and their use in gene therapy |
| WO2004056080A1 (en) * | 2002-12-18 | 2004-07-01 | Novartis Ag | Endothelial cell specifically binding peptides |
| CA2557326A1 (en) | 2004-02-24 | 2005-09-09 | Introgen Therapeutics, Inc. | Combination of ad-p53 and chemotherapy for the treatment of tumours |
| US20080063656A1 (en) * | 2004-08-09 | 2008-03-13 | Emini Emilio A | Adenoviral Vector Compositions |
| WO2006079176A1 (en) | 2005-01-28 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
| WO2007044441A2 (en) * | 2005-10-06 | 2007-04-19 | Schering Corporation | Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases |
| JP5513885B2 (ja) | 2006-07-31 | 2014-06-04 | ヴァスキュラー バイオジェニックス リミテッド | ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用 |
| US9567605B2 (en) | 2010-01-05 | 2017-02-14 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
| JP6151515B2 (ja) | 2010-01-05 | 2017-06-21 | バスキュラー バイオジェニックス リミテッド | 神経膠芽腫ｇｂｍを治療するための組成物および方法 |
| JP6009357B2 (ja) | 2010-01-12 | 2016-10-19 | バスキュラー バイオジェニックス リミテッド | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 |
| SI2908865T1 (sl) | 2012-10-17 | 2019-02-28 | Vascular Biogenics Ltd. | Adenovirus, ki izraža Fas himero in uporaba le-tega v postopkih zdravljenja raka |
-
2011
- 2011-01-05 US US13/520,457 patent/US9567605B2/en not_active Expired - Fee Related
- 2011-01-05 AU AU2011204405A patent/AU2011204405B2/en not_active Ceased
- 2011-01-05 KR KR1020127020566A patent/KR101754437B1/ko not_active Expired - Fee Related
- 2011-01-05 NZ NZ601324A patent/NZ601324A/en not_active IP Right Cessation
- 2011-01-05 CA CA2786374A patent/CA2786374C/en active Active
- 2011-01-05 WO PCT/IL2011/000007 patent/WO2011083464A2/en not_active Ceased
- 2011-01-05 MX MX2012007849A patent/MX342641B/es active IP Right Grant
- 2011-01-05 EP EP16196233.7A patent/EP3159405B8/en active Active
- 2011-01-05 EP EP11731733.9A patent/EP2521776B1/en active Active
- 2011-01-05 SG SG10201500013SA patent/SG10201500013SA/en unknown
- 2011-01-05 DK DK11731733.9T patent/DK2521776T3/en active
- 2011-01-05 DK DK16196233.7T patent/DK3159405T3/en active
- 2011-01-05 SG SG2012049581A patent/SG182367A1/en unknown
- 2011-01-05 JP JP2012547585A patent/JP6196040B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-12 US US13/797,160 patent/US20130280217A1/en not_active Abandoned
- 2013-03-12 US US13/796,991 patent/US20130280216A1/en not_active Abandoned
-
2017
- 2017-04-25 JP JP2017085788A patent/JP2017186341A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130139741A (ko) | 2013-12-23 |
| SG182367A1 (en) | 2012-08-30 |
| EP2521776B1 (en) | 2016-11-02 |
| DK2521776T3 (en) | 2017-02-13 |
| NZ601324A (en) | 2014-10-31 |
| CA2786374A1 (en) | 2011-07-14 |
| US9567605B2 (en) | 2017-02-14 |
| EP3159405B1 (en) | 2018-09-12 |
| SG10201500013SA (en) | 2015-03-30 |
| AU2011204405A1 (en) | 2012-08-30 |
| WO2011083464A2 (en) | 2011-07-14 |
| EP3159405A1 (en) | 2017-04-26 |
| JP2017186341A (ja) | 2017-10-12 |
| WO2011083464A3 (en) | 2011-11-10 |
| JP2013516454A (ja) | 2013-05-13 |
| EP2521776A2 (en) | 2012-11-14 |
| US20140010785A1 (en) | 2014-01-09 |
| CA2786374C (en) | 2019-01-22 |
| KR101754437B1 (ko) | 2017-07-05 |
| US20130280216A1 (en) | 2013-10-24 |
| AU2011204405B2 (en) | 2015-06-18 |
| US20130280217A1 (en) | 2013-10-24 |
| MX2012007849A (es) | 2012-10-09 |
| EP2521776A4 (en) | 2013-07-31 |
| JP6196040B2 (ja) | 2017-09-13 |
| DK3159405T3 (en) | 2019-01-07 |
| EP3159405B8 (en) | 2018-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX342641B (es) | Metodos para uso de un agente adenoviral anti-angiogenico especifico. | |
| HUE049886T2 (hu) | Tumorspecifikus neoantigéneket tartalmazó készítmények, tumorok kezelésében történõ alkalmazásra | |
| IL261338A (en) | Preparations and methods for treating broad-spectrum, undiagnosed or mixed clinical applications | |
| ZA201309016B (en) | Simian adenovirus and hybrid adenoviral vectors | |
| EP2595557A4 (en) | COMBINED PROCESSING SYSTEMS, METHODS AND APPARATUS FOR BODY MODELING APPLICATIONS | |
| NZ601325A (en) | Compositions and methods for treating glioblastoma gbm | |
| MX2015001716A (es) | Niclosamida para el tratamiento de tumores solidos. | |
| PL2468319T3 (pl) | Nowy nanoprodukt przydatny w zabiegach profilaktycznych, diagnostycznych oraz leczniczych w medycynie ludzkiej i w weterynarii | |
| IL236516A0 (en) | Methods and compositions for diagnosis and treatment of cancer | |
| IL238107B (en) | Compositions comprising masitinib for use in treatment of cancer in patient subpopulations identified using predictor factors | |
| WO2012170776A3 (en) | Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy | |
| IL220801A0 (en) | Pad, in particular for use in the nursing care and hospital sector | |
| BR112013000433A2 (pt) | diagnóstico e tratamento de câncer de mama | |
| SG11201400919RA (en) | Patient stratification and determining clinical outcome for cancer patients | |
| IL220661A0 (en) | Beta-carbolines for use in the treatment of hearing loss and vertigo | |
| MX2012007898A (es) | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. | |
| EP2641525A4 (en) | In vivo examination apparatus and capsule endoscope | |
| PL2436406T3 (pl) | Urządzenie do pozaustrojowego oczyszczania krwi | |
| EP2682459A4 (en) | ONCOLYTIC ADENOVIRES FOR A TEMPORARY THERAPY AND USE THEREOF | |
| WO2010086838A3 (en) | Non-ad5 adenoviral vectors and methods and uses related thereto | |
| TWD160732S (zh) | 美容器具用磁力衰減器之部分 | |
| IL212800A0 (en) | N-cadherin: target for cancer diagnosis and therapy | |
| SG10201605729TA (en) | Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy | |
| GB201121914D0 (en) | Method for patient selection | |
| PL2575924T3 (pl) | Urządzenie do obróbki krwi w trybie jednoigłowym |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |